Paola Chiani

List of Publications by Year
in descending order

36 papers	1,894 citations	361296 20 h-index	360920 35 g-index
36 all docs	36 docs citations	36 times ranked	1847 citing authors

#	Article	IF	Citations
1	Freeâ€ranging red deer (<i>Cervus elaphus</i>) as carriers of potentially zoonotic Shiga toxinâ€producing <i>Escherichia coli</i>. Transboundary and Emerging Diseases, 2022, 69, 1902-1911.	1.3	14
2	Population Analysis of O26 Shiga Toxin-Producing Escherichia coli Causing Hemolytic Uremic Syndrome in Italy, 1989â€“2020, Through Whole Genome Sequencing. Frontiers in Cellular and Infection Microbiology, 2022, 12, 842508.	1.8	4
3	Molecular characterization of diarrheagenic Escherichia coli isolates from children with diarrhea: A cross-sectional study in four provinces of Mozambique. International Journal of Infectious Diseases, 2022, 121, 190-194.	1.5	10
4	Genomic Characterization of hlyF-positive Shiga Toxinâ€“Producing Escherichia coli, Italy and the Netherlands, 2000â€“2019. Emerging Infectious Diseases, 2021, 27, 853-861.	2.0	10
5	Investigation on the Evolution of Shiga Toxin-Converting Phages Based on Whole Genome Sequencing. Frontiers in Microbiology, 2020, 11, 1472.	1.5	13
6	Characterization of a novel plasmid encoding F4-like fimbriae present in a Shiga-toxin producing enterotoxigenic Escherichia coli isolated during the investigation on a case of hemolytic-uremic syndrome. International Journal of Medical Microbiology, 2018, 308, 947-955.	1.5	17
7	A case of haemolytic uraemic syndrome (HUS) revealed an outbreak of Shiga toxin-2-producing Escherichia coli O26:H11 infection in a nursery, with long-lasting shedders and person-to-person transmission, Italy 2015. Journal of Medical Microbiology, 2018, 67, 775-782.	0.7	19
8	Comparative analysis of plantâ€produced, recombinant dimeric IgA against cell wall Î²â€glucan of pathogenic fungi. Biotechnology and Bioengineering, 2017, 114, 2729-2738.	1.7	5
9	The Gene <i>tia</i> , Harbored by the Subtilase-Encoding Pathogenicity Island, Is Involved in the Ability of Locus of Enterocyte Effacement-Negative Shiga Toxin-Producing Escherichia coli Strains To Invade Monolayers of Epithelial Cells. Infection and Immunity, 2017, 85, .	1.0	13
10	Antibodies against a Î²-glucan-protein complex of Candida albicans and its potential as indicator of protective immunity in candidemic patients. Scientific Reports, 2017, 7, 2722.	1.6	12
11	A Murine, Bispecific Monoclonal Antibody Simultaneously Recognizing Î²-Glucan and MP65 Determinants in Candida Species. PLoS ONE, 2016, 11, e0148714.	1.1	11
12	Candida albicans Targets a Lipid Raft/Dectin-1 Platform to Enter Human Monocytes and Induce Antigen Specific T Cell Responses. PLoS ONE, 2015, 10, e0142531.	1.1	16
13	Deciphering the structureâ€“immunogenicity relationship of anti-<i>Candida</i>glycoconjugate vaccines. Chemical Science, 2014, 5, 4302-4311.	3.7	55
14	Plant production of antiâ€Î²â€glucan antibodies for immunotherapy of fungal infections in humans. Plant Biotechnology Journal, 2011, 9, 776-787.	4.1	22
15	Hyr1 Protein and Î²â€Glucan Conjugates as Antiâ€<i>Candida</i>Vaccines. Journal of Infectious Diseases, 2010, 202, 1930-1930.	1.9	11
16	Endogenous PGE2 promotes the induction of human Th17 responses by fungal Î²-glucan. Journal of Leukocyte Biology, 2010, 88, 947-954.	1.5	41
17	A Î²-glucan-conjugate vaccine and anti-Î²-glucan antibodies are effective against murine vaginal candidiasis as assessed by a novel in vivo imaging technique. Vaccine, 2010, 28, 1717-1725.	1.7	74
18	Beta-glucan-CRM197 conjugates as candidates antifungal vaccines. Vaccine, 2010, 28, 2615-2623.	1.7	104

#	Article	IF	Citations
19	Protection by Anti-Î²-Glucan Antibodies Is Associated with Restricted Î²-1,3 Glucan Binding Specificity and Inhibition of Fungal Growth and Adherence. PLoS ONE, 2009, 4, e5392.	1.1	184
20	Anti-Î²-glucan antibodies in healthy human subjects. Vaccine, 2009, 27, 513-519.	1.7	52
21	Candida albicans cell wall comprises a branched Î²-d-(1â†’6)-glucan with Î²-d-(1â†’3)-side chains. Carbohydrate Research, 2008, 343, 1050-1061.	1.1	44
22	Î²-Glucan of<i>Candida albicans</i>cell wall causes the subversion of human monocyte differentiation into dendritic cells. Journal of Leukocyte Biology, 2007, 82, 1136-1142.	1.5	37
23	An Anti-Î²-Glucan Monoclonal Antibody Inhibits Growth and Capsule Formation of Cryptococcus neoformans In Vitro and Exerts Therapeutic, Anticryptococcal Activity In Vivo. Infection and Immunity, 2007, 75, 5085-5094.	1.0	152
24	A novel glyco-conjugate vaccine against fungal pathogens. Journal of Experimental Medicine, 2005, 202, 597-606.	4.2	409
25	Induction of protective immunity by Legionella pneumophila flagellum in an A/J mouse model. Vaccine, 2005, 23, 4811-4820.	1.7	26
26	The interaction of human dendritic cells with yeast and germ-tube forms ofCandida albicansleads to efficient fungal processing, dendritic cell maturation, and acquisition of a Th1 response-promoting function. Journal of Leukocyte Biology, 2004, 75, 117-126.	1.5	62
27	Candida albicans Yeast and Germ Tube Forms Interfere Differently with Human Monocyte Differentiation into Dendritic Cells: a Novel Dimorphism-Dependent Mechanism To Escape the Host's Immune Response. Infection and Immunity, 2004, 72, 833-843.	1.0	51
28	Antiretroviral Therapy with Protease Inhibitors Has an Early, Immune Reconstitutionâ€“Independent Beneficial Effect onCandidaVirulence and Oral Candidiasis in Human Immunodeficiency Virusâ€“Infected Subjects. Journal of Infectious Diseases, 2002, 185, 188-195.	1.9	79
29	Deletion of the Two-Component Histidine Kinase Gene (CHK1) of Candida albicans Contributes to Enhanced Growth Inhibition and Killing by Human Neutrophils In Vitro. Infection and Immunity, 2002, 70, 985-987.	1.0	44
30	Interplay between Protective and Inhibitory Antibodies Dictates the Outcome of Experimentally Disseminated Candidiasis in Recipients of a Candida albicans Vaccine. Infection and Immunity, 2002, 70, 5462-5470.	1.0	89
31	Defective Induction of Interleukin-12 in Human Monocytes by Germ-Tube Forms of Candida albicans. Infection and Immunity, 2000, 68, 5628-5634.	1.0	38
32	Suckling CD1 mice as an animal model for studies of Legionella pneumophila virulence. Journal of Medical Microbiology, 1997, 46, 647-655.	0.7	10
33	Possible participation of polymorphonuclear cells stimulated by microbial immunomodulators in the dysregulated cytokine patterns of AIDS patients. Journal of Leukocyte Biology, 1997, 62, 60-66.	1.5	25
34	Responsiveness of human polymorphonuclear cells (PMNL) to stimulation by a mannoprotein fraction (MP-F2) of Candida albicans ; enhanced production of IL-6 and tumour necrosis factor-alpha (TNF-Î±) by MP-F2-stimulated PMNL from HIV-infected subjects. Clinical and Experimental Immunology, 1997, 107, 451-457.	1.1	21
35	Elevated aspartic proteinase secretion and experimental pathogenicity of Candida albicans isolates from oral cavities of subjects infected with human immunodeficiency virus. Infection and Immunity, 1996, 64, 466-471.	1.0	120
36	Protection against Lethal Challenge by <i>Legionella pneumophila</i> in A/J Mice Following Immunization with Flagella. , 0, , 129-132.		0